Questcor Reaches New 52-Week High (QCOR) - TheStreet



) --

Questcor Pharmaceuticals



) hit a new 52-week high Friday as it is currently trading at $52.12, above its previous 52-week high of $52.10 with 621,515 shares traded as of 12:20 p.m. ET. Average volume has been 1.8 million shares over the past 30 days.

Questcor has a market cap of $3.25 billion and is part of the

health care

sector and


industry. Shares are up 21.9% year to date as of the close of trading on Thursday.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides prescription drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. The company has a P/E ratio of 31.8, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

TheStreet Ratings rates Questcor as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full

Questcor Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center